5-[2-(5,6-diethyl-indan-2-ylamino)-ethyl]-8-hydroxy-1H-quinolin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-[2-(5,6-diethyl-indan-2-ylamino)-ethyl]-8-hydroxy-1H-quinolin-2-one
• 英文别名: 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]ethyl]-8-hydroxy-1H-quinolin-2-one
• 化学式: C₂₄H₂₈N₂O₂
• 分子量: 376.499
• InChiKey: ZQWNZUAMWNPQGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  茚达特罗 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 20.08h， 生成 5-[2-(5,6-diethyl-indan-2-ylamino)-ethyl]-8-hydroxy-1H-quinolin-2-one
  参考文献：
  名称：

  An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol

  摘要：

  The synthesis of a series of indacaterol analogues in which each of the three structural regions of indacaterol are modified in a systematic manner is described. Evaluation of the affinity of these analogues for the beta(2)-adrenoceptor identified the 3,4-dihydroquinolinone and 5-n-butylindanyl analogues to demonstrate the most similar profiles to indacaterol. An alpha-methyl aminoindane analogue was discovered to be 25-fold more potent than indacaterol, and functional studies revealed an atypical beta(2)-adrenoceptor activation profile for this compound consistent with that of a slowly dissociating 'super agonist'. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.096

文献信息

• [EN] PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2009087224A1

  公开（公告）日：2009-07-16

  Compounds of formula (I) in free or salt or solvate form, where T1, T2, and T3 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式（I）的化合物以自由形式、盐形式或溶剂合物形式存在，其中T1、T2和T3的含义如规范中所示，可用于治疗炎症性或阻塞性气道、肺动脉高压、肺纤维化、肝纤维化、肌肉疾病和全身骨骼疾病。还描述了含有这些化合物的药物组合物和制备这些化合物的方法。
• [EN] HETEROCYCLIC OXIME COMPOUNDS<br/>[FR] COMPOSÉS D'OXIMES HÉTÉROCYCLIQUES
  申请人：NOVARTIS AG

  公开号：WO2011020861A1

  公开（公告）日：2011-02-24

  The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  该发明涉及公式(I)的化合物及其盐，其中取代基如规范中所定义；公式(I)的化合物用于治疗人体或动物体，特别是针对c-Met酪氨酸激酶介导的疾病或症状；公式(I)的化合物用于制造治疗此类疾病的药物；包含公式(I)的化合物的药物组合物，可选地与组合伙伴一起，并且用于制备公式(I)的化合物的方法。
• INHALABLE FORMULATION OF A SOLUTION CONTAINING INDACATEROL MALEATE AND GLYCOPYRRONIUM BROMIDE
  申请人：Huang Cai Gu

  公开号：US20200375945A1

  公开（公告）日：2020-12-03

  The present invention discloses a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprising: (a) active substances selected from glycopyrronium bromide and indacaterol maleate; (b) a solvent; and (c) a pharmacologically acceptable preservative, optionally including a pharmacologically acceptable stabilizer, a pharmacologically acceptable solubilizing agent, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.

  本发明公开了一种无推进剂液体制剂的药物制备方法，以及通过在雾化器中雾化药物制剂来给药的方法。该无推进剂药物制剂包括：（a）从格隆溴铵和吲达帕尼马来酸盐中选择的活性物质；（b）溶剂；以及（c）药理学上可接受的防腐剂，可选地包括药理学上可接受的稳定剂、药理学上可接受的溶解剂、药理学上可接受的共溶剂或其他药理学上可接受的添加剂。
• [EN] BETA2-ADRENOCEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR BETA 2-ADRENERGIQUE
  申请人：NOVARTIS AG

  公开号：WO2000075114A1

  公开（公告）日：2000-12-14

  Compounds of formula (I) in free or salt or solvate form, where Ar is a group of formula (II) Y is carbon or nitrogen and R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10¿, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. The compounds of formula (I) in free, salt or solvate form, have β2-adrenoreceptor agonist activity.

  公式（I）的化合物，其自由形式、盐形式或溶剂化合物形式中，其中Ar是公式（II）的基团，Y是碳或氮，R?1，R2，R3，R4，R5，R6，R7，R8，R9，R10，X，n，p，q和r如规范所定义，它们的制备以及它们作为药物的用途，特别是用于治疗阻塞性或炎性呼吸道疾病。公式（I）的化合物在自由、盐或溶剂化合物形式中具有β2-肾上腺素受体激动剂活性。
• Beta2-adrenoceptor agonists
  申请人：Cuenoud Bernard

  公开号：US20050153957A1

  公开（公告）日：2005-07-14

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  该文描述的是公式中自由或盐或溶剂形式的化合物，其中Ar是公式的一组，Y是碳或氮，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义在规范中，它们的制备以及它们作为药物的用途，特别是用于治疗阻塞性或炎性气道疾病。